Literature DB >> 30136054

Potential negative impact of informing patients about medication side effects: a systematic review.

Jimmy Jose1, Lamia AlHajri2,3.   

Abstract

Background Pharmacovigilance, as it is carried out primarily by healthcare professionals is more focused on being very objective in nature. Acknowledging the importance of the subjective experience of patients in pharmacovigilance was underpinned by its unique ability to bring about a more holistic understanding through the deep information unraveled by the patients. Medication safety-related information has to be shared with patients to allow them to be actively involved in their therapy and pharmacovigilance. Despite the advantages of sharing information, it stands to reasons whether sharing information related to possible side effects would negatively affect patients and impinge upon their treatment plan and process. Aim of the Review The purpose of this systematic review was to critically assess the potential negative impact of informing patients about medication side effects by written and/or oral information on medication compliance, occurrence/development of suspected side effects and clinical outcomes. Method A comprehensive search was conducted in PubMed, and Cochrane library to identify potential records between the year 1975 and 2017; then titles, abstracts, and full texts were screened using the inclusion criteria to filter out irrelevant studies. The data extraction, and the results were narratively synthesized and presented in tables. Results A total of 2012 articles were screened for inclusion, 32 full-text articles were assessed for eligibility and finally resulting in the inclusion of 17 randomized control studies which met the set criteria. Findings unraveled that the educational intervention did not result in increased occurrence/reporting of side effects in most of the evaluated studies; except 4 studies, and no significant impact on compliance to medications and negative clinical outcome was observed. Apprehension of negative events to medications were observed in two of the four studies which evaluated these parameters. Conclusion The present review did not find enough evidence to support the over concerns on the potential negative impact of sharing of information on the adverse effects to patients, though the influence could manifest as nocebo-effect. The various components and methods employed for this information sharing process can influence the potential impact of this activity. These concerns about the undesirable effects should not deter the active involvement of patients in pharmacovigilance activities. There is a definite need to have more studies in this area, where much of concern still does exist among the various stakeholders of drug safety information.

Entities:  

Keywords:  Adverse drug reactions; Drug safety information; Nocebo effect; Patient education; Pharmacovigilance; Side effects

Mesh:

Year:  2018        PMID: 30136054     DOI: 10.1007/s11096-018-0716-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  61 in total

1.  A survey on the knowledge, beliefs and behaviour of a general adult population in Malaysia with respect to the adverse effects of medicines.

Authors:  Jimmy Jose; David Chong; Tay Szu Lynn; Goh Ee Jye; Beena Jimmy
Journal:  Int J Pharm Pract       Date:  2011-04-15

2.  Informed consent and tardive dyskinesia.

Authors:  I Kleinman; D Schachter; E Koritar
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

3.  How much information about adverse effects of medication do patients want from physicians?

Authors:  D K Ziegler; M C Mosier; M Buenaver; K Okuyemi
Journal:  Arch Intern Med       Date:  2001-03-12

4.  To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent.

Authors:  Rebecca Erwin Wells; Ted J Kaptchuk
Journal:  Am J Bioeth       Date:  2012       Impact factor: 11.229

5.  Patients' use of the Internet for medical information.

Authors:  Joseph A Diaz; Rebecca A Griffith; James J Ng; Steven E Reinert; Peter D Friedmann; Anne W Moulton
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

6.  Informed consent to opioid agonist maintenance treatment: recommended ethical guidelines.

Authors:  Adrian Carter; Wayne Hall
Journal:  Int J Drug Policy       Date:  2008-02

7.  Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?

Authors:  Nicola Mondaini; Paolo Gontero; Gianluca Giubilei; Giuseppe Lombardi; Tommaso Cai; Andrea Gavazzi; Riccardo Bartoletti
Journal:  J Sex Med       Date:  2007-07-26       Impact factor: 3.802

8.  Erectile dysfunction after therapy with metoprolol: the Hawthorne effect.

Authors:  G Cocco
Journal:  Cardiology       Date:  2008-07-24       Impact factor: 1.869

9.  Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis.

Authors:  Johanna Carolina Rojas-Mirquez; Milton Jose Max Rodriguez-Zuñiga; Francisco Javier Bonilla-Escobar; Herney Andres Garcia-Perdomo; Mike Petkov; Lino Becerra; David Borsook; Clas Linnman
Journal:  Front Behav Neurosci       Date:  2014-11-03       Impact factor: 3.558

10.  Learning to experience side effects after antidepressant intake - Results from a randomized, controlled, double-blind study.

Authors:  Julia Rheker; Alexander Winkler; Bettina K Doering; Winfried Rief
Journal:  Psychopharmacology (Berl)       Date:  2016-11-02       Impact factor: 4.530

View more
  9 in total

1.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08

2.  The Unintended Consequences of Adverse Event Information on Medicines' Risks and Label Content.

Authors:  Giovanni Furlan; David Power
Journal:  Pharmaceut Med       Date:  2020-11-16

3.  Minimizing Drug Adverse Events by Informing About the Nocebo Effect-An Experimental Study.

Authors:  Yiqi Pan; Timm Kinitz; Marin Stapic; Yvonne Nestoriuc
Journal:  Front Psychiatry       Date:  2019-07-25       Impact factor: 4.157

4.  The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.

Authors:  Justine M Z van Tongeren; S Froukje Harkes-Idzinga; Heleen van der Sijs; Roya Atiqi; Bart J F van den Bemt; L Willem Draijer; Deline Hiel; Adrian Kerremans; Bart Kremers; Marc de Leeuw; Marleen V Olthoff; T Kim-Loan Pham; Ricky Valentijn-Robertz; Kayan Tsoi; Iris Wichers; Maaike de Wit; Sander D Borgsteede
Journal:  Front Pharmacol       Date:  2020-05-15       Impact factor: 5.810

5.  Communication on drug safety-related matters to patients: is it even more significant in this digital era?

Authors:  Jimmy Jose
Journal:  Ther Adv Drug Saf       Date:  2020-04-09

6.  A simulation-based module in pharmacology education reveals and addresses medical students' deficits in leading prescription talks.

Authors:  Verena Kirsch; Jan Matthes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-09-15       Impact factor: 3.195

7.  Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine

Authors:  Manuel Vélez-Díaz-Pallarés; Teresa Gramage-Caro; Miguel Ángel Rodríguez-Sagrado; Beatriz Montero-Llorente; Teresa Bermejo-Vicedo
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

8.  Effect of Briefing on Acupuncture Treatment Outcome Expectations, Pain, and Adverse Side Effects Among Patients With Chronic Low Back Pain: A Randomized Clinical Trial.

Authors:  Jürgen Barth; Stefanie Muff; Alexandra Kern; Anja Zieger; Stefanie Keiser; Marco Zoller; Thomas Rosemann; Benno Brinkhaus; Leonhard Held; Claudia M Witt
Journal:  JAMA Netw Open       Date:  2021-09-01

9.  Aspects of Medication and Patient participation-an Easy guideLine (AMPEL). A conversation guide increases patients' and physicians' satisfaction with prescription talks.

Authors:  Verena Kirsch; Jan Matthes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-06-09       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.